✦ LIBER ✦

PDB19 ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL

✍ Scribed by A Brennan; M Gillett; A Duenas

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDB43 Economic Evaluation of Vildaglipti

✍ Hatzikou, M.; Rombopoulos, G.; Yfantopoulos, J. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PDB62 COST-UTILITY ANALYSIS OF SAXAGLIPT

✍ FG Eliaschewitz; E Asano; ME Nita; R Rached; BM Donato 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

Cost-Effectiveness of Dapagliflozin as A

✍ van Haalen, H.G.M.; Pompen, M.; Bergenheim, K.; McEwan, P.; Townsend, R.; Roudau 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

196: Cost-Effectiveness of Aliskiren as

✍ James L. Palmer; Veronica C. Munk; Robert W. Kotchie; Gabor Vincze; Alan Charney 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Cost-effectiveness and budget impact of

✍ Nita, Marcelo Eidi; Eliaschewitz, Freddy G.; Ribeiro, Eliane; Asano, Elio; Barbo 📂 Article 📅 2012 🏛 Elsevier ⚖ 107 KB

PCV34 THE COST-EFFECTIVENESS OF ALISKIRE

✍ JL Palmer; VC Munk; R Kotchie; G Vincze; Charney k; D Tucker; L Annemans 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB